| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | Neutral → Neutral |
| 06/06/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | Neutral → Neutral |
| 05/18/2023 | 140.32% | Citigroup | $17 → $18 | Maintains | Buy |
| 05/09/2023 | 153.67% | Stifel | $18 → $19 | Maintains | Buy |
| 03/31/2023 | 20.16% | JP Morgan | $8 → $9 | Maintains | Neutral |
| 03/21/2023 | 60.21% | Wells Fargo | → $12 | Assumes | → Overweight |
| 03/21/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | → Neutral |
| 03/10/2023 | 126.97% | Citigroup | $21 → $17 | Maintains | Buy |
| 03/08/2023 | 113.62% | Guggenheim | → $16 | Reiterates | → Buy |
| 01/24/2023 | 6.81% | HC Wainwright & Co. | → $8 | Reiterates | → Neutral |
| 01/20/2023 | 33.51% | SVB Leerink | $8 → $10 | Maintains | Market Perform |
| 01/04/2023 | 6.81% | HC Wainwright & Co. | $10 → $8 | Maintains | Neutral |
| 12/22/2022 | 20.16% | Barclays | $7 → $9 | Maintains | Equal-Weight |
| 12/20/2022 | 46.86% | Jefferies | $7.7 → $11 | Upgrades | Hold → Buy |
| 11/21/2022 | 33.51% | HC Wainwright & Co. | $8 → $10 | Maintains | Neutral |
| 11/01/2022 | 6.81% | HC Wainwright & Co. | $40 → $8 | Downgrades | Buy → Neutral |
| 10/24/2022 | 140.32% | Stifel | $21 → $18 | Maintains | Buy |
| 10/21/2022 | 6.81% | SVB Leerink | $19 → $8 | Downgrades | Outperform → Market Perform |
| 10/04/2022 | 20.16% | Wells Fargo | $45 → $9 | Assumes | → Overweight |
| 09/14/2022 | 180.37% | Citigroup | $27 → $21 | Maintains | Buy |
| 08/26/2022 | 260.48% | Citigroup | $28 → $27 | Maintains | Buy |
| 05/27/2022 | 153.67% | SVB Leerink | $18 → $19 | Maintains | Outperform |
| 05/23/2022 | 434.05% | HC Wainwright & Co. | $44 → $40 | Maintains | Buy |
| 05/09/2022 | 273.83% | Citigroup | $30 → $28 | Maintains | Buy |
| 05/09/2022 | 273.83% | Citigroup | $30 → $28 | Maintains | Buy |
| 05/05/2022 | 86.92% | Guggenheim | → $14 | Upgrades | Neutral → Buy |
| 03/15/2022 | 100.27% | Evercore ISI Group | → $15 | Initiates Coverage On | → Outperform |
| 02/28/2022 | 300.53% | Citigroup | $53 → $30 | Maintains | Buy |
| 02/09/2022 | 540.85% | Wells Fargo | $56 → $48 | Maintains | Overweight |
| 12/10/2021 | 887.98% | Raymond James | → $74 | Downgrades | Strong Buy → Outperform |
| 12/10/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 11/10/2021 | 260.48% | SVB Leerink | $28 → $27 | Maintains | Market Perform |
| 11/04/2021 | 273.83% | SVB Leerink | $43 → $28 | Maintains | Market Perform |
| 08/05/2021 | 487.45% | HC Wainwright & Co. | $55 → $44 | Maintains | Buy |
| 05/07/2021 | 634.31% | HC Wainwright & Co. | $57 → $55 | Maintains | Buy |
| 03/31/2021 | 634.31% | Credit Suisse | → $55 | Initiates Coverage On | → Outperform |
| 02/25/2021 | 447.4% | SVB Leerink | $50 → $41 | Downgrades | Outperform → Market Perform |
| 02/08/2021 | 661.01% | HC Wainwright & Co. | → $57 | Assumes | → Buy |
| 01/25/2021 | 607.61% | Citigroup | $50 → $53 | Downgrades | Buy → Neutral |
| 01/19/2021 | 887.98% | Raymond James | $60 → $74 | Maintains | Strong Buy |
| 01/12/2021 | 781.17% | SVB Leerink | $45 → $66 | Maintains | Outperform |
| 08/06/2020 | 500.8% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 07/09/2020 | 620.96% | HC Wainwright & Co. | $60 → $54 | Maintains | Buy |
| 06/02/2020 | 567.56% | Citigroup | $49 → $50 | Maintains | Buy |
| 03/03/2020 | 701.07% | HC Wainwright & Co. | $65 → $60 | Reiterates | → Buy |
| 02/03/2020 | 834.58% | Stifel | $45 → $70 | Maintains | Buy |
| 01/15/2020 | 674.37% | Wells Fargo | $48 → $58 | Maintains | Overweight |
| 01/10/2020 | 714.42% | Wolfe Research | → $61 | Initiates Coverage On | → Outperform |
| 12/09/2019 | 474.1% | JP Morgan | → $43 | Initiates Coverage On | → Neutral |
| 11/25/2019 | 767.82% | HC Wainwright & Co. | → $65 | Initiates Coverage On | → Buy |
| 11/25/2019 | 701.07% | Raymond James | $40 → $60 | Maintains | Strong Buy |
| 11/20/2019 | 540.85% | Guggenheim | → $48 | Initiates Coverage On | → Buy |
| 10/29/2019 | 420.69% | Deutsche Bank | $36 → $39 | Maintains | Buy |
| 09/30/2019 | 434.05% | Raymond James | $36 → $40 | Upgrades | Outperform → Strong Buy |
| 08/30/2019 | 500.8% | Stifel | → $45 | Initiates Coverage On | → Buy |
| 08/27/2019 | 554.21% | Citigroup | $22 → $49 | Maintains | Buy |
| 08/05/2019 | 207.08% | Barclays | $15 → $23 | Maintains | Equal-Weight |
| 07/18/2019 | 353.94% | Deutsche Bank | → $34 | Initiates Coverage On | → Buy |
What is the target price for Zymeworks (ZYME)?
The latest price target for Zymeworks (NASDAQ: ZYME) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $8.00 expecting ZYME to rise to within 12 months (a possible 6.81% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zymeworks (ZYME)?
The latest analyst rating for Zymeworks (NASDAQ: ZYME) was provided by HC Wainwright & Co., and Zymeworks reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for Zymeworks (ZYME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Zymeworks (ZYME) correct?
While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a reiterated with a price target of $0.00 to $8.00. The current price Zymeworks (ZYME) is trading at is $7.49, which is within the analyst's predicted range.